Диссертации эмболизация маточных артерий при миоме матки
1. Абуладзе ДА. К вопросу о сохраняющем способе удаления посредством межуточных и под-слизистых фибромиом матки чревосечения. Киев; 1902. 2. 3.
2. Александров МС. Хирургическое лечение фибромиом матки. Василевская ЛН. Об обменных процессах в миометрии при Гальстер МН. Патоморфо логическая характеристика узлов Москва: Медгиз; 1958. миоме матки. Акушерство и гинекология 1970,9:129-135. при фибромиоме матки. Сборник научных трудов Владивостокского мед. института 1972:7:269-270.
3. Голубчин СБ. Новое в консервативной хирургии фибромиом 10. матки. Труды Хабаровского медицинского института. Сб. 1950:стр. 124-133 6. И.А.Яковлева БГК. Морфологическая диагностика предопухолевых 7. процессов и опухолей матки по биопсиям и АЭ. Сравнительная оценка оперативных соскобам. Кишинев; 1
4. Мандельштам методов лечения миом матки. Труды V1IL1 Всесоюзного съезда акушеров и гинекологов 1930:стр. 27-45. 8.
5. Хмельницкий ОК. Пато морфологическая диагностика гинеколо-гических заболеваний. -Петербург: СОТИС; 1
6. Adachi К, Karachi Н, Homma Н, et al. Estrogen induces epidermal growth factor (EGF) receptor and its ligands in human fallopian lube: involvement of EGF but not transforming growth factor-alpha in estrogen-induced tubal cell growth in vitro. Endocrinology 1995;136(5):2110-9.
7. Amato P, Roberts AC. Transient ovarian failure: a complication of Andersen J. Growth factors and cytokines in uterine leiomyomas. Andrews RT, Bromley PJ, Pfister ME. Successful embolization of uterine artery embolization. Fertil Sterii 2001;75(2):438-
8. Semin Reprod Endocrinol 1996;14(3):269-82. collaterals from the ovarian artery during uterine artery embolization for fibroids: a case report. J Vase Interv Radiol 2000; 11(5):607-10. 14.
9. Andrews RT, Brown PH. Uterine arterial embolization: factors Ariel A, Sozen I. Transforming growth factor-beta3 is expressed at influencing patient radiation exposure. Radiology 2000;217(3):7I3-22. high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Sterii 2000;73(5): 1006-11. 16.
10. Armstrong C, Caird L. Fibroid embolisation: a technique not Arredondo-Soberon F, Loret de Mola JR, S Man sky-Goldberg R, without significant complications. Bjog 2001; 108( 1):
11. Tureck RW. Uterine arteriovenous malformation in a patient with recurrent pregnancy loss and a bicornuate uterus. A case report. J Reprod Med 1997;42(4):239-43.
12. Athanasoulis CA, Waltman AC, Barnes AB, Herbst AL. Angiographic control of pelvic bleeding from treated carcinoma of the cervix. Gynecol Oncol 1976;4(2):144-50.
13. Aungst M, Wilson M, Vournas K, McCarthy S. Necrotic leiomyoma and gram-negative sepsis eight weeks after uterine artery embolization. Obstet Gynecol 2004;104(5 Pt 2): 1161-4. 20. Bai SW, Jang JB, Lee do Y, et al. Uterine arterial embolization for the treatment of uterine leiomyomas. Yonsei Med J 2002,43(3):346-50.
14. Banovac F, Ascher SM, Jones DA, et al. Magnetic resonance of tris-acryl gelatin microspheres. J Vase lnterv Radiol imaging outcome after uterine artery embolization for leiomyomata with 2002;i3(7):681-
15. Beller U, Rosen RJ, Beckman EM, et al. Congenital arteriovenous malformation of the female pelvis: a gynecologic perspective. Am J Obstet Gynecol 1988;159(5):1153-60.
16. Benditt EP. Evidence for a monoclonal origin of human plaques and some implications. Circulation atherosclerotic 1974,50(4):650-2.
17. Bhugra B, Smolarek ТА, Lynch RA, et al. Cloning of a breakpoint cluster region on chromosome 14 in uterine leiomyoma. Cancer Lett 1998:126(2):119-26. 25.
18. Bianchi S, Fedele L. The GnRH agonists in the treatment of uterine Blank C, Rogalla P, Tran KH, Bullerdiek J. A novel high mobility and other benign tumors. Cancer Genet Cytogenei leiomyomas. Acta Eur Fertil 1989;20(1):5-10. group protein gene is a candidate for Xp22 abnormalities in uterine leiomyomas 2000; 121(2): 172-80. 27.
19. Bonatz G, Frahm SO, Andreas S, et al. Telomere shortening in Brandon DD, Bethea CL, Strawn ЕУ, et al. Progesterone receptor uterine leiomyomas. Am J Obstet Gynecol 1998;179{3 Pt l):591-6. messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993,169(l):78-85.
20. Brosens I, Johannisson E, Dal Cin P, et al. Analysis of the menopausal, and gonadotropin-releasing hormone karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, agonist-treated females. Fertil Steril 1996;66(3):376-9.
21. Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and ils product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 1994,78(3):736-43.
22. Butnor KJ, Burchette JL, Robboy SJ. Progesterone receptor activity in leiomyomatosis peritonealis disseminata. Int J Gynecol Pathol 1999;18(3):259-64.
23. Caresano A, Del Favero C, Confalonieri C, Li Rosi G. [Selective arterial embolization in uterine cancer hemorrhage (results obtained in 4 cases)]. Ann Ostet Ginecol Med Perinat I979;100(2):131-8.
24. Catherino WH, Leppert PC, Stenmark MH, et a]. Reduced link between uterine dermatopontin expression is a molecular 17.
25. Chang FW, Ding DC, Chen DC, Yu MH. Heavy uterine bleeding leiomyomas and keloids. Genes Chromosomes Cancer 2004;40(3):204- due to uterine arteriovenous malformations. Acta Obstet Gynecol Scand 2004,83 (6):599-600.
26. Chapman DR, Lutz MH. Report of a successful delivery after management of a choriocarcinoma-related pelvic nonsurgical 36. arteriovenous fistula. Am J Obstet Gynecol 1985; 153(2): 155-
27. Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol 2003;209(1-2):916.
28. Chegini N, Tang XM, Ma C. Regulation of transforming growth factor-betal expression by granulocyte macrophage-colony-stimulating factor in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 1999;84(11):4138-43.
29. Chen С, Liu P, Lu J, et al. [Uterine arterial embolization in the treatment of adenomyosis]. Zhonghua Fu Chan Ke Za Zhi 2002;37(2):77Chiesa AG, Hart WR. Uterine artery embolization of leiomyomas with trisacryl gelatin microspheres (TGM): pathologic features and comparison with polyvinyl alcohol emboli. Int J Gynecol Pathol 2004,23(4) :3 86-92.
30. Choo YC, Cho KJ. Pelvic abscess complicating embolic therapy for control of bleeding cervical carcinoma and simultaneous radiation therapy. Obstet Gynecol 1980;55(3 Suppl):76S-78S.
31. Clapp JF, 3rd, Szeto HH, Larrow R, et al. Umbilical blood flow response to embolization of the uterine circulation. Am J Obstet Gynecol 1980;138(l):60-7.
32. Coigan TJ, Pron G, Mocarski EJ, et al. Pathologic features of uteri and leiomyomas following uterine artery embolization for leiomyomas. Am J Surg Pathol 2003;27(2): 167-77.
33. Coutinho EM, Boulanger GA, Goncalves MT. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone. Am J Obstet Gynecol 1986;155(4):761-7. 44. Dal Cin P, Quade BJ, Neskey DM, et al. Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(ql5;q24). Genes Chromosomes Cancer 2003,36(2):205-6.
34. Dawood MY, Khan-Dawood FS. Plasma insulin-like growth facior-I, CA-125, estrogen, and progesterone in women with leiomyomas. FertilSterill994;61(4):617-21. 46. Di Lieto A, De Rosa G, De Falco M, et al. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment. Hum Pathol 2002;33(2):220-4.
35. Fedele L, Vercetlmi P, Bianchi S, et al. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br J Obstet Gynaecol 1990;97(S):393-6.
36. Fletcher JA, Longtine J, Wallace K, et al. Cytogenetic and Fan SX, Sreekantaiah C, Berger CS, et al. Cytogenetic findings in nine leiomyomas of the uterus. Cancer Genet Cytogenet 1990:47(2): 179- histologic findings in 17 pulmonary chondroid hamartomas: evidence for a pathogenetic relationship with lipomas and leiomyomas. Genes Chromosomes Cancer 1995;12(3):220-3. 51. 52. 7. 53.
37. Fujimoto J, Hirose R, Ichigo S, et al. Expression of progesterone receptor form A and В mRNAs in uterine leiomyoma. Tumour Biol 1998;19(2):126-31.
38. Fujimoto J, Hirose R, Sakaguchi H, Tamaya T. Expression of size- polymorphic androgen receptor gene in uterine leiomyoma according to the number of cytosine, adenine, and guanine repeats in androgen receptor alleles. Tumour Bioi 2000;21(l):33-7.
39. Fujimoto J, Hori M, Ichigo S, Tamaya T. Expression of basic fibroblast growth factor and its mRNA in uterine endometrial cancers. Invasion Metastasis 1995;15(5-6):203-10.
40. Fujimoto J, Ichigo S, Sakaguchi H, et al. Expression of plateletderived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Cancer Lett 1998; !30( 1-2): 115-20.
41. Giudice LC, Irwin JC, Dsupin BA, et al. Insulin-like growth factor (IGF), IGF binding protein (IGFBP). and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 1993;8(ll):1796-806.
42. Giuliani L, Carmignani G, Belgrano E, et al. Total pelvic arterial embolization in a case of massive vesical and vaginal bleeding by pelvis carcinomatosis. Eur Urol 1979;5(3):205-7. 61.
43. Goldberg J, Pereira L, Berghella V. Pregnancy after uterine artery Goldberg J, Pereira L, Berghella V, et al. Pregnancy outcomes after for fibromyomata: uterine artery embolization versus embolization. Obstet Gynecol 2002;100(5 Pt l);869-72. treatment 63. laparoscopic myomectomy. Am J Obstet Gynecol 2004,191(l):!8-2i. Goldstein HM, Medellin H, Ben-Menachem Y, Wallace S. Transcatheter arterial embolization in the management of bleeding in the cancer patient. Radiology 1975;115(3):603-8.
44. Gross KL, Neskey DM, Manchanda N, et al. HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 2003;38(1):68-79.
45. Gulati MS, Srinivasan A, Paul SB, Bhatla N. Uterine restoration following fibroid expulsion after uterine artery embolisation using gelfoam. J Postgrad Med 2004;50(1):80.
46. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 1995;80(6): 1853-8.
47. Hascalik S, Celik O, Sarac K, Hascalik M. Transient ovarian failure; a rare complication of uterine fibroid embolization. Acta Obstet Gynecol Scand 2004;83(7):682-5.
48. Havel G, Dahlenfors R, Wedell B, et al. Cytogenetical observations and hormone receptor expression in five extra-uterine leiomyomas. Anticancer Res 1994;14{5A):1935-7.
49. Hayashi S, Miharu N, Okamoto E, et al. Detection of chromosomal 12 in uterine leiomyoma using abnormalities of chromosome 70. fluorescence in situ hybridization. Jpn J Hum Genet 1996;41(1): 193-
50. Hennig Y, Deichert U, Stem C, et al. Structural aberrations of chromosome 6 in three uterine smooth muscle tumors. Cancer Genet Cytogenet 1996;87(2):148-51.
51. Hennig Y, Rogalla P, Wanschura S, et al. HMG1C expressed in a uterine leiomyoma with a deletion of the long arm of chromosome 7 along with a 12ql4-15 rearrangement but not in tumors showing del(7) as the sole cytogenetic abnormality. Cancer Genet Cytogenet 1997;96(2):129-33.
52. Higgins CB, Bookstein JJ, Davis GB, et al. Therapeutic for intractable chronic bleeding. Radiology embolization 73. 1977;122(2):473
53. Hodges LC, Houston KD, Hunter DS, et al. Transdominant suppression of estrogen receptor signaling by progesterone receptor
54. Genes Chromosomes Cancer uterine leiomyoma t(12;14)(ql3-l5;q24.1) breakpoint on chromosome 14 between 75. 1994;ll(4):263-
55. Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. EnvironHealthPerspect2000;108Suppl 5:785-90.
56. Jautzke G, Muller-Ruchholtz E, Thalmann U. Immunohisiological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Pathol Res Pract 1996; 192(3):215-23.
57. Jeffers MD, Richmond JA, Macaulay EM. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas. Mod Pathol 1995;8(7):70l-4. 78. Jha RC, Takahama J, Imaoka I, et al. Adenomyosis: MRJ of the uterus treated with uterine artery embolization. AJR Am J Roentgenol 2003;181(3):851-6.
58. Jiang J, Wu RF, Wang ZH, et al. Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 2002;77(5):995-1000.
59. Johansson M, Dietrich C, Mandahl N, et al. Recombinations of bands 6p21 and !4q24 characterise pulmonary chromosomal hamartomas. Br J Cancer 1993;67(6): 1236-41. 81.
60. Karaiskos C, Pandis N, Bardi G, et al. Cytogenetic findings in uterine epithelioid leiomyomas. Cancer Genet Cytogenet 1995; 80(2): 103-
61. Kataoka S, Yamada H, Hoshi N, et al. Cytogenetic analysis of uterine leiomyoma: the size, histopathology and GnRHa-response in relation to chromosome karyotype. Eur J Obstet Gynecol Reprod Biol 2003;110(l):58-62. 83. for
62. Katsumori T, Akazawa K, Mihara T. Uterine artery embolization pedunculated subserosal fibroids. AJR Am J Roentgenol 2005;184(2):399-
63. Katsumori T, Nakajima K, Mihara T. Is a large fibroid a high-risk factor for uterine artery embolization? AJR Am J Roentgenol 2003;181(S):1309-14.
64. Kazmierczak B, Dal Cin P, Wanschura S, et al. HMGIY is the target of 6p2L3 rearrangements in various benign mesenchymal tumors. Genes Chromosomes Cancer 1998;23(4):279-85.
65. Kelemen J, Scultety S, Nemeth A, Szegvari M. Embolization of the arteria iliaca interna as treatment of life-end angering haemorrhages caused by intrapelvic malignant tumours. Diagn Imaging 1979:48(5):27585.
66. Keyoung JA, Levy EB, Roth AR, et al. Intraarterial lidocaine for pain control after uterine artery embolization for leiomyomata. J Vase Itterv Radiol 2001;12(9):1065-9.
67. Kitawaki J, Koshiba H, Ishihara H, et al. Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium. J Clin Endocrinol Metab 2000;85(9):3292-6.
68. Kobayashi TK, Ueda M, Nishino T, et al. Cellular changes following uterine artery embolization for the treatment of adenomyosis. Cytopathology 2001;12(4):270-2.
69. Kostal M, Tosner J, Natekova J, Rouskova L. [Pregnancy after uterine artery embolization in uterine myoma]. Ceska Gynekol 2004;69(i):48-50.
70. Lefebvre GG, Vilos G. Asch M. Uterine fibroid embolization Lessl M, Klotzbuecher M, Schoen S, et al. Comparative messenger (UFE). J Obstet Gynaecol Can 2004;26(10):899-911,913-28. ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyoma and healthy myometrium. J Clin Endocrinol Metab 1997;82(8):2596-600.
71. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. Bjog2002;109(10):1097-108.
72. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001(2):CD000547.
73. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2000(2):CD000547.
74. Levy В, Mukherjee T, Hirschhorn К. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet 2000; 121 (1): 1-8.
75. Ligon AH, Morton CC. Leiomyomata: heritabiiity and cytogenetic studies. Hum Reprod Update 2001;7(I):8-14.
76. Ligon AH, Morton CC. Genetics of uterine leiomyomata. Genes Chromosomes Cancer 2000;28(3):235-45. 102. Liu P, Chen C, Liu L, Liu J. [Investigation of the hemodynamic changes during uterine arterial embolization in the treatment of adenomyosis]. Zhonghua Fu Chan Ke Za Zhi 2002;37(9):536-8.
77. Lynch RA, Piper M, Bankier A, el al. Genomic and functional map of the chromosome 14 t(12;14) breakpoint cluster region in uterine leiomyoma. Genomics 1998;52(l):17-26.
78. Mangrulkar RS, Ono M, Ishikawa M, et al. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod 1995;53(3):636-46.
79. Marelli G, Codegoni AM, Bizzi A. Estrogen and progesterone receptors in leiomyomas and normal uterine tissues during reproductive life. Acta Eur Ferti! 1989;20(1): 19-22.
80. Mark J, Havel G, Dahlenfors R. Wedell B. Cytogenetics of multiple uterine leiomyomas, parametrial leiomyoma and disseminated peritoneal leiomyomatosis. Anticancer Res 1991;ll(l):33-9.
81. Mark J, Havel G, Grepp C, et al. Chromosomal patterns in human benign uterine leiomyomas. Cancer Genet Cytogenet 1990:44(1): 1-13.
82. Marret H, Alonso AM, Cottier JP, et al. Leiomyoma recurrence after uterine artery embolization. J Vase Interv Radiol 2003;14(11):13959.
83. Marugo M, Centonze M, Bemasconi D, et al. Estrogen and progesterone receptors in uterine leiomyomas. Acta Obstet Gynecol Scandl989;68(8):731-5.
84. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000,65(10-11):58592.
85. Maruo T, Matsuo H, Shimomura Y, et al. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids 2003:68(10-13): 817-24.
86. Mashal RD, Fejzo ML, Friedman AJ, et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer 1994;ll(l):l6.
87. Massart F, Becherini L, Marini F, et al. Analysis of estrogen receptor (ERalpha and ERfaeta) and progesterone receptor (PR) polymorphisms in uterine leiomyomas. Med Sci Monit 2003;9{l):BR2530.
88. Matsuo H, Maruo T, Samoto T Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997;82(I):293-9. 116. McLucas B. Adler L. Re: Leiomyoma recurrence after uterine artery embolization. J Vase Interv Radiol 2004;15(7):773-4, author reply 774-5. 117. McLucas B, Goodwin S, Adler L, et al. Pregnancy following uterine fibroid embolization. Int J Gynaecol Obstet 2001;74(l):I-7.
89. Miller FJ, Jr., Mortel R, Mann WJ, Jahshan AE. Selective arterial embolization for contro! of hemorrhage in pelvic malignancy: femoral and brachial catheter approaches. AJR Am J Roentgenol 1976; 126(5): 1028-32.
90. Moore AB, He H, Yoshida A, et al. Transforming growth factoralpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3FI mice. Exp Toxicol Pathol 2000j52(3): 195-200.
91. Moss NS, Benditt EP. Human atherosclerotic plaque cells and leiomyoma ceils. Comparison of in vitro growth characteristics. Am J Pathol 1975;78(2): 175-90. 124 Mugneret F, Lizard-Nacol S, Volk C, et al. Association of breakpoint !4q23 with uterine leiomyoma. Cancer Genet Cytogenet 1988,34(2}:201-6.
92. Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76(2):513-7.
93. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril !995;64(I):187-90.
94. Nardelli GB, Mega M, Bertasi M, Siliotti F. Estradiol and progesterone binding in uterine leiomyomata and pregnant myometrium. Clin Exp Obstet Gynecol 1987; 14(3-4): 155-60.
95. Nikolic B, Abbara S, Levy E, et al. Influence of radiographic technique and equipment on absorbed ovarian dose associated with uterine artery embolization. J Vase Interv Radiol 2000;11(9):1173-8.
96. Nikolic B, Spies JB, Lundsten MJ, Abbara S. Patient radiation dose associated with uterine artery embolization. Radiology 2000;214{I):1215.
97. Oliver JA, Jr., Lance JS. Selective embolization to control massive hemorrhage following pelvic surgery. Am J Obstet Gynecol 1979;135(3):43I-2.
98. Orii A, Mori A,Zhai YL, eta!. Mast cells in smooth muscle tumors of the uterus. Int J Gynecol Pathol 1998;17(4):336-42.
99. Packenham JP, du Manoir S, SchrockE, et al. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog 1997;19(4):273-9.
100. Payne JF, Haney AF. Serious complications of uterine artery embolization for conservative 2003;79(1): 128-31.
101. Pearson ТА, Dillman JM, SolexK, Heptinstall RH. Clonal markers in the study of the origin and growth of human atherosclerotic lesions. CircResl978;43(l):10-8.
102. Pelage JP, Jacob D, Le Dref O, Laurent A. Re: Leiomyoma recurrence after uterine artery embolization. J Vase Interv Radiol 2004;15(7):773; author reply 774-5.
103. Pollow K, Geilfuss J, Boquoi E, Pollow B. Estrogen and progesterone binding proteins in normal human myometrium and leiomyoma tissue. J Clin Chem Clin Biochem 1978;16<9):503-11. treatment of fibroids. Fertil Steril
104. Poncelet С, Madelenat P, Feldmann G, et al. Expression of von Willebrands factor, CD34, CD31, and vascular endothelial growth factor in uterine leiomyomas. Fertil Steril 2002;78(3):581-6.
105. Potgieter HC, Magagane F, Bester MJ. Oestrogen and progesterone receptor status and PgR/ER ratios in normal and myomatous human myometrium. East Afr Med J 1995;72<8):510-4
106. Prollius A, de Vries C, Loggenberg E, et al. Utenne artery embolisation for symptomatic fibroids: the effect of the large uterus on outcome. Bjog 2004;111(3):239-42.
107. Prollius A, de Vries C, Loggenberg E, et al. Uterine artery embolization for symptomatic fibroids. Int J Gynaecol Obstet 2004;84(3):236-40.
108. PronG, Mocarski E, Bennett J, et al. Pregnancy after utenne artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005;105(l):67-76.
109. Radeleff B, Rimbach S, Kauffmann GW, Richter GM. [Risk and complication rate of uterine fibroid embolization (UFE)]. Radiologe 2003 ;43(8):641-50.
110. Rajan DK, Beecroft JR, Clark TW, et al. Risk of intrauterine infectious complications after uterine artery embolization. J Vase Interv Radiol 2004;15(12):1415-21.
111. Rasuli P, Jolty ЕЕ, Hammond I, et al. Superior hypogastric nerve block for pain control in outpatient uterine artery embolization. J Vase Interv Radiol 2004;I5(12):1423-9.
112. Rauk PN, Surti U, Roberts JM, Michalopoulos G. Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells. Am J Obstet Gynecol 1995;173(2):5717.
113. Ravina JH, Aymard А, С iraru-Vigneron N, et al. [Uterine fibroids embolization: results about 454 cases]. Gynecol Obstet Fertil 2003;31(78):597-60S.
114. Ravina JH, Bouret JM. Fried D, et al. [Value of preoperative embolization of uterine fibroma: report of a multicenter series of 31 cases]. Contracept Fertil Sex 1995;23(l):45-9.
115. Ravina JH, Herbreteau D, С iraru-Vigneron N, et al. Arterial embolisation to treat uterine myomata. Lancet 1995;346(8976):671-2.
116. Ravina JH, Merland JJ, Ciraru-Vigneron N, et al. [Arterial embolization: a new treatment of menorrhagia in uterine fibroma]. Presse Medl995;24(37):1754.
117. Ravina JH, Merland J J, Herbreteau D, et al. [Preoperative embolization of uterine fibroma. Preliminary results (10 cases)]. Presse Med 1994;23(33):I540.
118. Ravina JH, Vigneron NC, Aymard A, et al. Pregnancy after embolization of uterine myoma: report of 12 cases. Fertil Steril 2000,73(6): 1241-3.
119. Razavi MK, Wolanske KA, Hwang GL, et al. Angiographic classification 12.
120. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995;] 72(1 Pt!):14-8.
121. Rein MS, Friedman AJ, Barbieri RL, et al. Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol 199k77(6):923-6.
122. Rein MS, Friedman AJ, Pandian MR, Heffner LJ. The secretion of insulin-like growth factors I and II by expiant cultures of fibroids and of ovarian artery-to-uterine artery anastomoses: initial observations in uterine fibroid embolization Radiology 2002;224<3):707-
123. Rein MS, Powell WL, Walters FC, et al. Cytogenetic abnormalities in uterine myomas are associated with myoma size. Mol Hum Reprod 1998;4(l):83-6.
124. Richter GM, Radeleff B, Rimbach S, Kauftmann GW. [Uterine fibroid embolization with spheric mi его-particles using flow guiding: safety, technical success and clinical results]. Rofo 2004;176(11):164857.
125. Robson S, Wilson K, Munday D, Sebben R. Pelvic sepsis complicating embolization of a uterine fibroid. Aust N Z J Obstet Gynaecol 1999;39(4):5I6-7.
126. Roth AR. Spies JB, Walsh SM, et al. Pain after uterine artery embolization for leiomyomata: can its severity be predicted and does severity predict outcome? J Vase Interv Radiol 2000; 11(8): 1047-52.
127. Ryan JM, Gainey M, Glasson J, et al. Simplified pain-control protocol after uterine artery embolization Radiology 2002,224(2):610-1; discussion 611-3. 161. Ryu RK, Omary RA, Sichlau MJ, et al. Comparison of pain after uterine artery embolization using tris-acryl gelatin microspheres versus polyvinyl alcohol particles. Cardiovasc Intervent Radiol 2003;26(4):3758.
128. Sadan O, van Iddekinge B, van Gelderen Ci, et al. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 1987;24 (Pt 3):263-7.
129. Salt SN, Dal Cm P, Ovanessoff S, Sandberg AA. A uterine leiomyoma showing both t(12;14) and del(7) abnormalities. Cancer Genet Cytogenetl989;37(2):157-61.
130. Sakakibara H, Taga M, Saji M, et al. Gene expression of epidermal growth factor in human endometrium during decidual ization. J Clin Endocrinol Metab 1994;79(l):223-6.
131. Salmi A, Rutanen FM. C-fos and c-jun expression in human endometrium and myometrium. Mol Cell Endocrinol 1996;117(2):23340. 166. Shi YF, Xie X, Zhao CL. [Histological diagnosis and clinical features in borderline smooth muscle tumors of the uterus]. Zhonghua Fu ChanKeZaZhi 1994;29(4):201-4,251.
132. Shozu M, Murakami K, Inoue M. Aromatase and leiomyoma of the uterus. Semin Reprod Med 2004;22(1):51-60.
133. Shozu M, Sumitani H, Segawa T, et al. Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate. J Clin Endocrinol Metab 2001 ;86(11):5405-11.
134. Siskin GP, Bonn J, Worth ington-Kirsch RL, et al. III. Uterine fibroid embolization: pain management. Tech Vase Interv Radiol 2002;5(l):35-43.
135. Siskin GP, Stainken BF, Dowling K, et al. Outpatient uterine artery embolization for symptomatic uterine fibroids: experience in 49 patients. J Vase Interv Radiol 2000;11(3):3Q5-11.
136. Smith DC, Wyatt JF. Embolization of the hypogastric arteries in the control of massive vaginal hemorrhage. Obstet Gynecol 1977;49(3):317-22.
137. Smith SJ, Sewall LE, Handelsman A. A clinical failure of uterine fibroid embolization due to adenomyosis. J Vase Interv Radio! 1999;10(9);1171-4.
138. Sozen I, Arid A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril2002;78(l):l-12.
139. Spies JB, Spector A, Roth AR, et al. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 2002; 100(5 Pt l):873-80.
140. Sreekantaiah C, Sandberg AA. Clustering of aberrations to specific chromosome regions in benign neoplasms. Int J Cancer 1991;48(2):1948.
141. Sterling KM, Vogelzang RL, Chrisman HB, et al. V. Uterine fibroid embolization: management of complications. Tech Vase Interv Radiol 2002;5(l):56-66.
142. Strawn EY, Jr., Novy MJ, Burry KA, Bethea CL. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am J Obstet Gynecol 1995; 172(6): 1837-43; discussion 1843-4.
143. Sutton CJ. Treatment of large uterine fibroids. Br J Obstet Gynaecol 1996;103(6):494-6.
144. Tailini G, Dal Cin P. HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 1999;6(5):23746.
145. Tailini G, Vanni R, Manfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest 2O00;80(3): 359-69.
146. Tamaya T, Motoyama T, Ohono Y, et al. Estradiol-17 beta-, progesterone and 5 alpha-dihydrotestosterone receptors of uterine myometrium and myoma in the human subject. J Steroid Biochem 1979; 10(6}:615-22.
147. Taylor CV, Letarte M, Lye SJ. The expression of integrins and cadhenns in normal human uterus and uterine leiomyomas. Am J Obstet Gynecol 1996;175(2):411-9.
148. Tiltman AJ. Smooth muscle neoplasms of the uterus. Curr Opin Obstet Gynecol 1997;9(1):48-51. 184. Toh CH, Wu CH, Tsay PK, et al. Uterine artery embolization for symptomatic uterine leiomyoma and adenomyosis. J Formos Med Assoc 2003; 102(10)701-6.
149. Toolin E, Pollack HM, McLean GK, et al. Ureteroarterial fistula: a case report. J Urol 1984,132(3):553-4.
150. Topfer LA, Hailey D. Uterine artery embolization for the treatment of fibroids. Issues Emerg Health Technol 2002(36):I-6.
151. Tropeano G, Litwicka K, Di Stasi C, et al. Permanent amenorrhea associated with endometrial atrophy after uterine artery embolization for symptomatic uterine fibroids. Fertil Steril 2003;79(1): 132-5.
152. Uzumcu M, Homsi MF, Ball DK, et al. Localization of connective tissue growth factor in human uterine tissues. Mol Hum Reprod 2000;6(l2):1093-8.
153. Vashishl A, Smith JR, Thorpe-Beeston G, McCall J. Pregnancy subsequent to uterine artery embolization. Fertil Steril 2001;75(6):12468.
154. Vashisht A, Studd J, Carey A, Bum P. Fatal septicaemia after fibroid embolisation- Lancet 1999;354(9175):307-8.
155. Vashisht A, Studd JW, Carey AH, et al. Fibroid embolisation: a technique not without significant complications. Bjog 2000; 107(9): 116670.
156. Vavala V, Lanzone A, Monaco A, et al. Postoperative GnRH analog treatment for the prevention of recurrences of uterine myomas after myomectomy. A pilot study. Gynecol Obstel Invest 1997;43(4):2514.
157. Vercellini P, Trespidi L, Zaina B, et al. Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial. Fertil Steril 2003;79{6):1390-S.
158. Vetter S, Schultz FW, Strecker EP, Zoetelief J. Patient radiation exposure in uterine artery embolization of leiomyomata: calculation of organ doses and effective dose. Eur Radiol 2004; 14(5): 842-8.
159. Vollenhoven BJ, Herington AC, Healy DL. Epidermal growth factor and transforming growth factor-beta in uterine fibroids and myometrium. Gynecol Obstet Invest 1995;40(2): 120-4. 199. Vu TH, Yballe C, Boonyanit S, Hoffman AR. Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiom у о sarcomata. J Clin Endocrinol Metab 1995;80(5): 1670-6.
160. Wagner SC, Gonsalves CF, Eschelman DJ, et al. Complications of a percutaneous suture-mediated closure device versus manual compression for arteriotomy closure: a case-controlled study. J Vase Interv Radiol 2003;14(6):735-41.
161. Walker W, Worthington-Kirsch RL. Fatal septicaemia after fibroid embolisation. Lancet 1999;354(9191):1730.
162. Wang HS, Wang TH, Soong YK. Elevation of insulin-like growth factor-binding protein-1 mRNA expression following hormone replacement therapy. Hum Reprod 2000,15(1 ):50-4. 203- Wang S, Su Q, Zhu S, et al. Clonality of multiple uterine leiomyomas- Zhonghua Bing Li Xue Za Zhi 2002;31 (2): 107-11.
163. Wanschura S, Kazmierczak B, Schoenmakers E, et al. Regional fine mapping of the multiple-aberration region involved in uterine leiomyoma, lipoma, and pleomorphic adenoma of the salivary gland to 12qI
164. Genes Chromosomes Cancer 1995; 14(1 ):68-70.
165. Watts HF. Basic aspects of the pathogenesis of human atherosclerosis. Hum Pathol 1971;2(l):31-55.
166. Williams AJ, Poweli WL, Collins T, Morton CC. HMGI(Y) expression in human uterine leiomyomata. Involvement of another highmobility group architectural factor in a benign neoplasm. Am J Pathol 1997;150(3):911-8.
167. Winterbauer RH, Elfenbein IB, Ball WC, Jr. Incidence and clinical significance of tumor embolization to the lungs. Am J Med 1968;45(2):271-90.
168. Worthington-Kirsch RL, Koller NE. Time course of pain after uterine artery embolization for fibroid disease. Medscape Womens Health 2002;7(2):4.
169. Worthington-Kirsch RL, Siskin GP. Uterine artery embolization for symptomatic myomata. J Intensive Care Med 2004; 19(1): 13-21. 210. Wu X, Blanck A, Olovsson M, et al. Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment. Acta Obstet Gynecol Scand 2001;80(6):497-504.
170. Yamada T, Nakago S, Kurachi 0, et al. Progesterone downregulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod 2004; 19(4):815-21.
171. Yamaki J, Yamamoto T, Okada H. Aromatization of androstenedione by normal and neoplastic endometrium of the uterus. J Steroid Biochem 1985;22(l):63-6.
172. Zhang H, Gu M, Wang C. [The expression of the receptors of estrogen, progesterone, epidermal growth factor and growth hormone in uterine adenomyosis and a comparative study after treatment with androgen]. Zhonghua Fu Chan Ke Za Zhi 1999;34(4):2I0-3.
173. Zupi E, Pocek M, Dauri M, et al. Selective uterine artery embolization in the management of uterine myomas. Fertil Steril 2003;79(1):I07-11.
